Sjögren's disease & overlap diseases
CD8+ tissue-resident memory T cells are expanded in primary Sjögren's disease and can be therapeutically targeted by CD103 blockade
Authors' conclusion
CD103+CD8+Trm cells are expanded in the SG of pSS and ESS, participate in tissue inflammation and can be therapeutically targeted.
Study context
- Population
- Primary Sjogren's syndrome (pSS) and non-pSS sicca syndrome patients (salivary glands (SG) and peripheral blood (PB)); immunisation-induced ESS mouse model
- Comparison
- pSS vs non-pSS sicca syndrome (non-specific sialadenitis (nSS)); in ESS mice, intraglandular CD103 blockade
- Outcome
- Trm in SG
Methodological detailsbulk and single-cell RNA sequencing, experimental SS (ESS) mouse model, intraglandular anti-CD103 monoclonal antibody
- Bulk and single-cell RNA sequencing
- Experimental SS (ESS) mouse model
- Intraglandular anti-CD103 monoclonal antibody
Main finding
As reported in the abstract
- Upregulation in pSS SG of genes associated with tissue recruitment and long-term survival of Trm cells
- Higher frequency of CD8+CD103+CD69+ cells in pSS SG vs nSS
- CD8+ CD103+ Trm contributed to secretion of granzyme-B and interferon-γ in SG
- CD8+ Trm localised within inflammatory infiltrates; PD1+CD8+ T cells increased vs nSS and MALT lymphoma
- Single-cell RNA sequencing (scRNAseq) confirmed expression of CD69, ITGAE, GZMB, GZMK and HLA-DRB1 among CD3+CD8+ SG T cells
- In ESS SG, CD8+CD69+CD103+ Trm producing Granzyme B progressively expanded
- Intraglandular CD103 blockade in ESS reduced Trm, reduced glandular damage and improved salivary flow
Original publication
CD8+ tissue-resident memory T cells are expanded in primary Sjögren's disease and can be therapeutically targeted by CD103 blockade. Ann Rheum Dis. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →